CY1124532T1 - Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf - Google Patents
Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tfInfo
- Publication number
- CY1124532T1 CY1124532T1 CY20211100669T CY211100669T CY1124532T1 CY 1124532 T1 CY1124532 T1 CY 1124532T1 CY 20211100669 T CY20211100669 T CY 20211100669T CY 211100669 T CY211100669 T CY 211100669T CY 1124532 T1 CY1124532 T1 CY 1124532T1
- Authority
- CY
- Cyprus
- Prior art keywords
- drug
- dosage forms
- antibody conjugate
- antibody
- week
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217320P | 2015-09-11 | 2015-09-11 | |
| PCT/EP2016/071336 WO2017042352A1 (en) | 2015-09-11 | 2016-09-09 | Dosing regimens for anti-tf-antibody drug-conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124532T1 true CY1124532T1 (el) | 2022-07-22 |
Family
ID=56926176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100669T CY1124532T1 (el) | 2015-09-11 | 2021-07-26 | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190030178A1 (https=) |
| EP (2) | EP3347054B1 (https=) |
| JP (2) | JP6978409B2 (https=) |
| CY (1) | CY1124532T1 (https=) |
| DK (1) | DK3347054T3 (https=) |
| ES (1) | ES2877527T3 (https=) |
| HU (1) | HUE055109T2 (https=) |
| PL (1) | PL3347054T3 (https=) |
| PT (1) | PT3347054T (https=) |
| SI (1) | SI3347054T1 (https=) |
| WO (1) | WO2017042352A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102372245B1 (ko) | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
| IL274122B2 (en) * | 2017-11-02 | 2024-09-01 | Genmab As | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
| CN112105388A (zh) * | 2018-03-07 | 2020-12-18 | 展马博联合股份有限公司 | 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| AU2019321442A1 (en) * | 2018-08-16 | 2021-02-11 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| TWI844571B (zh) * | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| JP7406784B2 (ja) * | 2019-04-17 | 2023-12-28 | 国立大学法人金沢大学 | 卵巣癌の検出方法 |
| TW202131954A (zh) * | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| MX2022005222A (es) * | 2019-11-07 | 2022-06-08 | Genmab As | Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco. |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2326350B1 (en) * | 2008-09-08 | 2013-09-04 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| KR102372245B1 (ko) | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
-
2016
- 2016-09-09 HU HUE16765958A patent/HUE055109T2/hu unknown
- 2016-09-09 DK DK16765958.0T patent/DK3347054T3/da active
- 2016-09-09 PL PL16765958T patent/PL3347054T3/pl unknown
- 2016-09-09 EP EP16765958.0A patent/EP3347054B1/en active Active
- 2016-09-09 ES ES16765958T patent/ES2877527T3/es active Active
- 2016-09-09 JP JP2018512876A patent/JP6978409B2/ja active Active
- 2016-09-09 US US15/758,520 patent/US20190030178A1/en not_active Abandoned
- 2016-09-09 PT PT167659580T patent/PT3347054T/pt unknown
- 2016-09-09 SI SI201631250T patent/SI3347054T1/sl unknown
- 2016-09-09 WO PCT/EP2016/071336 patent/WO2017042352A1/en not_active Ceased
- 2016-09-09 EP EP21171350.8A patent/EP3919081A1/en not_active Withdrawn
-
2021
- 2021-07-26 CY CY20211100669T patent/CY1124532T1/el unknown
- 2021-08-12 JP JP2021131502A patent/JP2021181479A/ja active Pending
- 2021-12-10 US US17/548,436 patent/US20220265844A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI3347054T1 (sl) | 2021-08-31 |
| EP3919081A1 (en) | 2021-12-08 |
| HUE055109T2 (hu) | 2021-11-29 |
| EP3347054A1 (en) | 2018-07-18 |
| JP6978409B2 (ja) | 2021-12-08 |
| EP3347054B1 (en) | 2021-05-05 |
| DK3347054T3 (da) | 2021-07-19 |
| ES2877527T3 (es) | 2021-11-17 |
| PT3347054T (pt) | 2021-07-15 |
| US20220265844A1 (en) | 2022-08-25 |
| US20190030178A1 (en) | 2019-01-31 |
| JP2018532715A (ja) | 2018-11-08 |
| PL3347054T3 (pl) | 2021-11-29 |
| WO2017042352A1 (en) | 2017-03-16 |
| JP2021181479A (ja) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| MX381017B (es) | Compuestos peptidomiméticos y conjugados anticuerpo-fármaco de estos. | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA202090542A1 (ru) | Высококонцентрированные лекарственные формы придопидина | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| ES3061642T3 (en) | Dosing regimens for treatment of proliferative disorders | |
| JOP20230099A1 (ar) | تركيبات صيدلية | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага |